Extraintestinal manifestations in inflammatory bowel disease

Silvio Danese(IRCCS Ospedale San Raffaele)

World Journal of Gastroenterology

January 1, 2005

10.3748/wjg.v11.i46.7227

Cited by 374

Related Papers

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

|Gastroenterology|2021|2.6k

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

|The American Journal of Gastroenterology|2015|1.8k

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

|The Lancet|2022|383

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

|Gastroenterology|2016|329

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

|The Lancet|2022|312